NASDAQ:RYTM Rhythm Pharmaceuticals - RYTM Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $29.08 -1.39 (-4.56%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$28.75▼$30.5550-Day Range$23.31▼$34.2452-Week Range$3.04▼$34.99Volume483,720 shsAverage Volume569,961 shsMarket Capitalization$1.64 billionP/E RatioN/ADividend YieldN/APrice Target$30.89 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Rhythm Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside6.2% Upside$30.89 Price TargetShort InterestBearish16.35% of Float Sold ShortDividend StrengthN/ASustainability-1.80Upright™ Environmental ScoreNews Sentiment0.88Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.55) to ($3.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.23 out of 5 starsMedical Sector1030th out of 1,049 stocksPharmaceutical Preparations Industry501st out of 514 stocks 1.4 Analyst's Opinion Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.89, Rhythm Pharmaceuticals has a forecasted upside of 6.2% from its current price of $29.08.Amount of Analyst CoverageRhythm Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.35% of the float of Rhythm Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently increased by 1.15%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRhythm Pharmaceuticals has received a 63.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Anti-obesity medication (A08)", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Rhythm Pharmaceuticals is -1.80. Previous Next 2.7 News and Social Media Coverage News SentimentRhythm Pharmaceuticals has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Rhythm Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for RYTM on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.80% of the stock of Rhythm Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($3.55) to ($3.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -8.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -8.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhythm Pharmaceuticals has a P/B Ratio of 5.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Rhythm Pharmaceuticals (NASDAQ:RYTM) StockRhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Read More Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RYTM Stock News HeadlinesJanuary 27, 2023 | americanbankingnews.comRhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Increased to $40.00 by Analysts at The Goldman Sachs GroupJanuary 25, 2023 | marketwatch.comRhythm Machines Market 2023 Upcoming Trends and Forecast to 2028 | New Revenue Report by Prominent Players, and Incredible Growth OpportunitiesJanuary 29, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 25, 2023 | msn.comFitness Boxing 2: Rhythm and Exercise is Getting Surprise DLCJanuary 24, 2023 | msn.comThe Best Levels In The Rhythm Heaven SeriesJanuary 23, 2023 | finance.yahoo.comRhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl SyndromeJanuary 21, 2023 | americanbankingnews.comRhythm Pharmaceuticals' (RYTM) Buy Rating Reiterated at Canaccord Genuity GroupJanuary 19, 2023 | msn.com7 Best Rhythm Games On iOS And AndroidJanuary 29, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 13, 2023 | marketwatch.comAnalysis of Circadian Rhythm Sleep Disorder Market for the Period 2023 to 2028 : Development, Growth and Key FactorsJanuary 8, 2023 | marketwatch.comCircadian Rhythm Lighting Market Research Insights 2023-2028 [Latest Report]: Leading Players Analysis with Industry Size and ShareJanuary 4, 2023 | marketwatch.comRhythm Machine Market 2023 Size, Share Industry Analysis by Future Demand, Top Players, Opportunities, Revenue and Growth Rate Through 2030December 28, 2022 | seekingalpha.comRhythm Pharma: An Incremental Approach Works Well For SetmelanotideDecember 28, 2022 | msn.comRhythm! Discovery Center closes after busted water pipeDecember 14, 2022 | finance.yahoo.comShareholders have faith in loss-making Rhythm Pharmaceuticals (NASDAQ:RYTM) as stock climbs 7.8% in past week, taking one-year gain to 190%December 6, 2022 | msn.comRhythm Pharmaceuticals's Return On Capital Employed OverviewDecember 2, 2022 | msn.comCalls for Rhythm and Vines to drop Dizzee Rascal over assault convictionDecember 1, 2022 | finance.yahoo.comRhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap ConferenceNovember 23, 2022 | msn.comSir Dave Dobbyn, Dizzee Rascal added as final headliners for Rhythm and Vines 2022November 21, 2022 | finance.yahoo.comRhythm Pharmaceuticals Announces ▼IMCIVREE® (setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl SyndromeNovember 11, 2022 | finance.yahoo.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Lifting Their Price TargetsNovember 10, 2022 | finance.yahoo.comRhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Intrinsic Value Is Potentially 17% Below Its Share PriceNovember 8, 2022 | seekingalpha.comRhythm Pharmaceuticals, Inc. (RYTM) Q3 2022 Earnings Call TranscriptNovember 8, 2022 | finance.yahoo.comRhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE® (setmelanotide) in Bardet-Biedl Syndrome in The Lancet Diabetes and EndocrinologyNovember 8, 2022 | finance.yahoo.comRhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Lags Revenue EstimatesNovember 8, 2022 | finance.yahoo.comRhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business UpdateNovember 3, 2022 | finance.yahoo.comRhythm Pharmaceuticals Announces 11 Presentations at The Obesity Society’s Annual Meeting at ObesityWeek®See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RYTM Company Calendar Last Earnings11/08/2022Today1/29/2023Next Earnings (Estimated)3/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RYTM CUSIPN/A CIK1649904 Webwww.rhythmtx.com Phone(857) 264-4280Fax857-264-4299Employees140Year FoundedN/APrice Target and Rating Average Stock Price Forecast$30.89 High Stock Price Forecast$40.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+6.2%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,610,000.00 Net Margins-1,089.07% Pretax Margin-1,137.00% Return on Equity-72.83% Return on Assets-56.64% Debt Debt-to-Equity RatioN/A Current Ratio10.93 Quick Ratio10.93 Sales & Book Value Annual Sales$3.15 million Price / Sales520.21 Cash FlowN/A Price / Cash FlowN/A Book Value$5.65 per share Price / Book5.15Miscellaneous Outstanding Shares56,350,000Free Float54,207,000Market Cap$1.64 billion OptionableOptionable Beta1.89 Key ExecutivesDr. David P. Meeker M.D. (Age 69)Chairman, Pres & CEO Comp: $1.09MMr. Hunter C. Smith M.B.A. (Age 54)CFO & Treasurer Comp: $658.21kMr. Joseph Shulman (Age 48)Chief Technical Officer Comp: $555.66kMr. Yann Mazabraud (Age 50)Exec. VP & Head of International Comp: $693.62kMs. Jennifer L. Chien (Age 48)Exec. VP & Head of North America Comp: $597.46kMr. William T. Roberts (Age 44)Chief Accounting Officer Mr. David ConnollyHead of Investor Relations & Corp. CommunicationsMr. Jim FlahertySr. VP & Gen. CounselMs. Sarah RyanVP of Sales & MarketingMs. Pamela J. Cramer (Age 49)Chief HR Officer More ExecutivesKey CompetitorsPacira BioSciencesNASDAQ:PCRXCatalyst PharmaceuticalsNASDAQ:CPRXVerona PharmaNASDAQ:VRNAIronwood PharmaceuticalsNASDAQ:IRWDArvinasNASDAQ:ARVNView All CompetitorsInsiders & InstitutionsRice Hall James & Associates LLCSold 17,155 shares on 1/27/2023Ownership: 0.272%Assenagon Asset Management S.A.Sold 6,894 shares on 1/12/2023Ownership: 0.823%Hennion & Walsh Asset Management Inc.Bought 7,496 shares on 1/12/2023Ownership: 0.105%Bank of New York Mellon CorpBought 18,413 shares on 12/8/2022Ownership: 0.071%California State Teachers Retirement SystemBought 574 shares on 11/21/2022Ownership: 0.058%View All Insider TransactionsView All Institutional Transactions RYTM Stock - Frequently Asked Questions Should I buy or sell Rhythm Pharmaceuticals stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RYTM shares. View RYTM analyst ratings or view top-rated stocks. What is Rhythm Pharmaceuticals' stock price forecast for 2023? 7 Wall Street research analysts have issued 12-month target prices for Rhythm Pharmaceuticals' shares. Their RYTM share price forecasts range from $20.00 to $40.00. On average, they expect the company's share price to reach $30.89 in the next twelve months. This suggests a possible upside of 6.2% from the stock's current price. View analysts price targets for RYTM or view top-rated stocks among Wall Street analysts. How have RYTM shares performed in 2023? Rhythm Pharmaceuticals' stock was trading at $29.12 on January 1st, 2023. Since then, RYTM stock has decreased by 0.1% and is now trading at $29.08. View the best growth stocks for 2023 here. When is Rhythm Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. View our RYTM earnings forecast. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) announced its quarterly earnings data on Tuesday, November, 8th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($1.01) by $0.22. The business had revenue of $4.28 million for the quarter, compared to the consensus estimate of $5.36 million. Rhythm Pharmaceuticals had a negative net margin of 1,089.07% and a negative trailing twelve-month return on equity of 72.83%. What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT). When did Rhythm Pharmaceuticals IPO? (RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager. What is Rhythm Pharmaceuticals' stock symbol? Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM." Who are Rhythm Pharmaceuticals' major shareholders? Rhythm Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.82%), Rice Hall James & Associates LLC (0.27%) and Hennion & Walsh Asset Management Inc. (0.11%). Insiders that own company stock include David P Meeker, Hunter C Smith, Joseph Shulman, Nithya Desikan, Pamela J Cramer, Ra Capital Management, LP, Todd Foley, William T Roberts and Yann Mazabraud. View institutional ownership trends. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Rhythm Pharmaceuticals' stock price today? One share of RYTM stock can currently be purchased for approximately $29.08. How much money does Rhythm Pharmaceuticals make? Rhythm Pharmaceuticals (NASDAQ:RYTM) has a market capitalization of $1.64 billion and generates $3.15 million in revenue each year. The company earns $-69,610,000.00 in net income (profit) each year or ($3.58) on an earnings per share basis. How many employees does Rhythm Pharmaceuticals have? The company employs 140 workers across the globe. How can I contact Rhythm Pharmaceuticals? Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The official website for the company is www.rhythmtx.com. The company can be reached via phone at (857) 264-4280, via email at hannah.deresiewicz@sternir.com, or via fax at 857-264-4299. This page (NASDAQ:RYTM) was last updated on 1/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.